<DOC>
	<DOCNO>NCT00403819</DOCNO>
	<brief_summary>A phase III , multi-centre , double blind , placebo control , crossover study , follow open label post study follow-up , assess efficacy safety Movicol treatment chronic constipation child</brief_summary>
	<brief_title>Study Examine Efficacy Safety Movicol Treatment Chronic Constipation Children</brief_title>
	<detailed_description>After baseline period 1 ( one ) week , subject meet inclusion criterion enter treatment phase study . Patients randomise receive either Movicol match Placebo two ( 2 ) week . Following treatment phase , patient underwent two ( 2 ) -week placebo washout period prior cross receive alternative treatment e.g . patient take Movicol give match Placebo vice versa completion washout period two ( 2 ) week . On completion double blind treatment phase , patient give option participate eight ( 8 ) week open label post study follow-up . Patients participate post study follow-up receive Movicol .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>Male female patient ethnic origin eligible participate study follow criterion fulfil . informed consent obtain patient 's parent guardian assent child capable understanding study age 24 month 11 year experience constipation define : ≤2 complete bowel movement per week , least one following : pain defaecation ≥1 4 day 1/4 bowel movement strain 1/4 bowel movement hard lumpy stool patient symptoms present ≥3 month available complete study able comply requirement restriction list patient's/parent 's information document . Patients eligible participate study follow condition apply : faecal impaction history faecal impaction history intestinal perforation constipation paralytic ileus toxic megacolon Hirschsprungs disease severe inflammatory condition intestinal tract severe gastrooesophageal reflux complicate anaemia , haematemesis , respiratory aspiration , failure thrive recognise complication gastrooesophageal reflux patient currently receive 0.5mg/kg/day senna 1/2 sachet sodium picosulphate per day child &lt; 6 year 1 sachet sodium picosulphate per day child &gt; 6 year ( i.e . high dos stimulant laxative ) significant medical condition investigator 's opinion would effect suitability entry study patient previously receive Movicol previously participate study know hypersensitivity polyethylene ( PEG ) 3350 constituent Movicol patient diabetes placebo use study sucrose patient receive investigational drug last 3 month patient and/or parent investigator think could comply requirement protocol reason ( particularly relation reliable completion diary card )</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>